> Stem Cell Sciences says a new pact with the Myelin Repair Foundation will provide it with a stable supply of uniform human brain cells for their research program on multiple sclerosis. Report
> Canada's LAB Research--a non-clinical contract research organization--has raised $21.1 million in fresh financing for its expansion plans. Release
> A handful of drug makers released their earnings, and it's a mixed bag: some up, some down, some hit by one-time charges. Here's a roundup. Report
> PsychoGenics has inked a new drug discovery pact with Eli Lilly covering the evaluation of neuropsychiatric drug candidates. Report
> Chutes & Ladders: Genelabs Technologies CEO James Smith has resigned. The company chairman and CFO will run the company until a new CEO is hired on. Report
> The FDA has granted priority review status to Schering-Plough's Peginterferon Alfa-2b, an adjuvant treatment for Stage III melanoma, a rare skin cancer. Release
> If remorse is proportional to the amount you're willing to pay to absolve it, then Eli Lilly must be feeling pretty guilty about Zyprexa. Report
> Can we trust a Chinese manufacturer that not only sold contaminated cancer drugs but tried to cover up the fact? Apparently, the FDA thinks so. Report
> Good news, needle-phobes. South Korean researchers have successfully tested a new approach to delivering vaccines, applying it under the tongue rather than through a needle. Report
And Finally... See that other blue-eyed person at the next table? Go say hi, because genetics proves that you're related to a common ancestor. Release